8-K Announcements
6Material company update
May 26, 2026·SEC
Material company update
May 18, 2026·SEC
Material company update
Apr 15, 2026·SEC
Alaunos Therapeutics, Inc.(TCRT)Earnings, Financials & Key Ratios
TCRT•NASDAQ
$2.20
Price updated Jul 7, 2026
AboutAlaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.Show more
- Revenue$5K-50.0%
- EBITDA-$4M+12.3%
- Net Income-$4M+10.8%
- EPS (Diluted)-2.20+24.7%
- Gross Margin100%
- EBITDA Margin-84360%-75.4%
- Operating Margin-84500%-75.6%
- Net Margin-83520%-78.5%
- ROE-198.1%-77.2%
TCRT Price & Volume
Alaunos Therapeutics, Inc. (TCRT) stock price & volume — 10-year historical chart
Loading chart...
Terminal Liquidity Erosion Threatens Alaunos Clinical Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity insolvency risk
Key Thesis Takeaways
- Alaunos Therapeutics faces a critical existential threat as its cash reserves have dwindled to $354,000, representing a near-total depletion from the $6.1 million held in 2023Q4.
- The company lacks a functional commercial engine, with revenue effectively at zero, and continues to sustain massive accumulated deficits exceeding $925 million.
- Investors should exercise extreme caution as the firm's inability to generate positive free cash flow suggests an imminent liquidity event that may render current equity value worthless.
Verdict Logic
the company's cash position of $354,000 against ongoing quarterly operating losses indicates an imminent risk of insolvency that outweighs any potential upside from its clinical-stage research.
TCRT Growth Metrics
Alaunos Therapeutics, Inc. (TCRT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-49.16%
5 Years-
3 Years-88.04%
TTM-70%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-0.93%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM14.57%
Return on Capital
10 Years-100.03%
5 Years-118.94%
3 Years-153.66%
Last Year-200.43%
TCRT Recent Earnings
Alaunos Therapeutics, Inc. (TCRT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (73%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.59
—
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.40+89.1%
$3.69
Rev
$3,000+0.0%
$3,000
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.55+88.8%
$4.90
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.63+88.2%
$5.33
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.59 | — |
| Q2 2026 | Mar 31, 2026 | $0.40vs $3.69+89.1% | $3,000vs $3,000+0.0% |
| Q4 2025 | Nov 14, 2025 | $0.55vs $4.90+88.8% | — |
| Q3 2025 | Aug 14, 2025 | $0.63vs $5.33+88.2% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Alaunos Therapeutics, Inc. (TCRT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.20 | $5.37M | -1.00 | -50% | -83520% | -198.1% | — | |
| $4.35 | $1.56B | -3.99 | 60.6% | -123.9% | -50.17% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $1.07 | $139.01M | -1.07 | 266.65% | -1360.61% | -91.94% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — |
Compare TCRT vs Peers
Alaunos Therapeutics, Inc. (TCRT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TCRT SEC Filings & Documents
Alaunos Therapeutics, Inc. (TCRT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TCRT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TCRT Frequently Asked Questions
Alaunos Therapeutics, Inc. (TCRT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Alaunos Therapeutics, Inc.'s revenue?
Alaunos Therapeutics, Inc. (TCRT) reported $0.0M in revenue for fiscal year 2025. This represents a 74% increase from $0.0M in 2001.
How fast is Alaunos Therapeutics, Inc. growing?
Alaunos Therapeutics, Inc. (TCRT) saw revenue decline by 50.0% over the past year.
Is TCRT profitable?
Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $4.1M for fiscal year 2025.
Dividend & Returns
What is TCRT's return on equity?
Alaunos Therapeutics, Inc. (TCRT) has a return on equity (ROE) of -198.1%. Negative ROE indicates the company is unprofitable.
What is Alaunos Therapeutics, Inc.'s free cash flow?
Alaunos Therapeutics, Inc. (TCRT) had negative free cash flow of $3.2M in fiscal year 2025, likely due to heavy capital investments.